Skip to content
Icon

KOSELUGO - (10MG, 25MG ; Capsule)

SELUMETINIB SULFATE Astrazeneca
10MG, 25MG ; Capsule
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
None
None None
KOSELUGO is a kinase inhibitor indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).
Yes
KOSELUGO Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8
****** ******* **** *** ******* **** *** ******* **** *** ******* **** *** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, ****
** ********* ************* *********** ** *** ********** ******** ******* **** ******** ******* **** ** ********* ************* *********** ** *** ********** ************** *********** ************** *********** ************** *********** ************** ***********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
****** *** \ ********* *** **, **** ******* **** *** ****** *** ****
  1. *** *, **** : * ****** **** ********* *** **** ***** ** ********* *** ****** **. *,***,*** (***** **, ****). **** **** ********* ** **** ****, ** **** ******** **** ** *** *** ****** ****** ***** ** ***** **, ****.
  2. *** *, **** : * ****** **** ********* *** **** ***** ** ********* *** ****** **. *,***,*** (***** **, ****). **** **** ********* ** **** ****, ** **** ******** **** ** *** *** ****** ****** ***** ** **** **, ****.
  3. *** *, **** : * ****** **** ********* *** **** ***** ** ********* *** ****** **. *,***,*** (******** **, ****). **** **** ********* ** *** ****, ** **** ******** **** ** *** *** ****** ****** ***** ** **** **, ****.
  4. *** *, **** : * ****** **** ********* *** **** ***** ** ********* *** ****** **. *,***,*** (***** **, ****). **** **** ********* ** **** ****, ** **** ******** **** ** *** *** ****** ****** ***** ** ***** **, ****.
  5. *** *, **** : * **** ** ** ***** *** ***** ** *** ***.
  6. *** *, **** : * ****** **** ********* *** **** ***** ** ********* *** ****** **. *,***,*** (***** **, ****). **** **** ********* ** **** ****, ** **** ******** **** ** *** *** ****** ****** ***** ** **** **, ****.
  7. *** **, **** : ****** ******** *********** ***** *** **** ** *******.
  8. *** *, **** : * ****** **** ********* *** **** ***** ** ********* *** ****** **. *,***,*** (******** **, ****). **** **** ********* ** *** ****, ** **** ******** **** ** *** *** ****** ****** ***** ** **** **, ****.
  9. *** *, **** : *********** **** ****** **** ************ ** ****** **. '*** (***** **, ****), '*** (***** **, ****), '*** (***** **, ****) *** '*** (***** **, ****).

KOSELUGO - (5MG, 7.5MG ; Granules)

SELUMETINIB SULFATE Astrazeneca
5MG, 7.5MG ; Granules
Less Than $1000 mn
None None
Less Than 5
None
None None
KOSELUGO is a kinase inhibitor indicated for the treatment of pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).
Yes
KOSELUGO Patent 1 Patent 2 Patent 3 Patent 4
*** *********
** ********* ************* *********** ** *** ********** ******** ******* **** ******** ******* **** ** ********* ************* *********** ** *** **********
  1. *** *, **** : * ****** **** ********* *** **** ***** ** ********* *** ****** **. *,***,*** (***** **, ****). **** **** ********* ** **** ****, ** **** ******** **** ** *** *** ****** ****** ***** ** ***** **, ****.
  2. *** *, **** : * ****** **** ********* *** **** ***** ** ********* *** ****** **. *,***,*** (***** **, ****). **** **** ********* ** **** ****, ** **** ******** **** ** *** *** ****** ****** ***** ** **** **, ****.
  3. *** *, **** : * ****** **** ********* *** **** ***** ** ********* *** ****** **. *,***,*** (******** **, ****). **** **** ********* ** *** ****, ** **** ******** **** ** *** *** ****** ****** ***** ** **** **, ****.
  4. *** *, **** : * ****** **** ********* *** **** ***** ** ********* *** ****** **. *,***,*** (***** **, ****). **** **** ********* ** **** ****, ** **** ******** **** ** *** *** ****** ****** ***** ** ***** **, ****.
  5. *** *, **** : * ****** **** ********* *** **** ***** ** ********* *** ****** **. *,***,*** (***** **, ****). **** **** ********* ** **** ****, ** **** ******** **** ** *** *** ****** ****** ***** ** **** **, ****.
  6. *** *, **** : * ****** **** ********* *** **** ***** ** ********* *** ****** **. *,***,*** (******** **, ****). **** **** ********* ** *** ****, ** **** ******** **** ** *** *** ****** ****** ***** ** **** **, ****.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.